Sofosbuvir/velpatasvir for 12 vs 6 weeks for the treatment of recently acquired hepatitis C infection | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Sofosbuvir/velpatasvir for 12 vs 6 weeks for the treatment of recently acquired hepatitis C infection

Matthews GV, Bhagani S, Van der Valk M, et al. Sofosbuvir/velpatasvir for 12 vs 6 weeks for the treatment of recently acquired hepatitis C infection. J Hepatol. 2021;S0168-8278(21):00336-6.

Publication Type:

Journal Article

Authors:

Matthews, GV; Bhagani, S; Van der Valk, M; et, al

Source:

J Hepatol, Volume S0168-8278, Issue 21, p.00336-6 (2021)

Cited On:

Management of Acute HCV Infection

Export Citation:

RIS Format

Top